Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha 1b nebulization for adult COVID-19 in Wuhan
ChiCTR2000030480Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Mar 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human interferon alpha-1b in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Incidence of side effects. Started Mar 2020; status: recruiting.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030480.